Menu Search
Equities

Tempest Therapeutics Inc

TPST:NAQ

Tempest Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.39
  • Today's Change-0.020 / -1.38%
  • Shares traded196.40k
  • 1 Year change+184.36%
  • Beta-1.8383
Data delayed at least 15 minutes, as of Sep 20 2024 19:19 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, Tempest Therapeutics Inc increased its cash reserves by 25.56%, or 8.08m. Cash Flow from Financing totalled 35.60m or -- of revenues. In addition the company used 27.36m for operations while cash used for investing totalled 170.00k.
Cash flow per share-1.60
Price/Cash flow per share--
Book value per share0.6921
Tangible book value per share0.6921
More ▼

Balance sheet in USDView more

Tempest Therapeutics Inc appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 1.10% of the market capitalization can be attributed to its 39.23m and debt could be paid in full if management chose.
Current ratio2.17
Quick ratio--
Total debt/total equity0.6289
Total debt/total capital0.3861
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.